Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

BIO-RAD LABORATORIES, INC. Logo
Develops and manufactures products for life science research and clinical diagnostic markets.
United States of America
BIO
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden
BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea
086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France
ALBIO
BIO-TECHNE Corp Logo
Develops reagents and instruments for life sciences research and clinical diagnostic markets.
United States of America
TECH
Bioten Co., Ltd Logo
Develops biotech health supplements, animal feed additives, and functional cosmetics.
South Korea
289170
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany
BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia
BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland
BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom
BVXP

Talk to a Data Expert

Have a question? We'll get back to you promptly.